| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.009 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.007 | 0.9 |